Rhinomed (ASX:RNO) - Hisse Senedi Fiyatı, Haberler ve Analizler

RNO Stoklara Genel Bakış

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide.

RNO temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Risk Analizi

Earnings have declined by 8.2% per year over past 5 years

Does not have a meaningful market cap (A$12M)

Negative shareholders equity

Highly volatile share price over the past 3 months

Rhinomed Limited Rakipler

Invion

ASX:IVX

AU$13.5m

Cann Group

ASX:CAN

AU$20.2m

Firebrick Pharma

ASX:FRE

AU$12.0m

Emyria

ASX:EMD

AU$13.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Rhinomed
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.04
52 Haftanın En Yüksek Seviyesi	AU$0.10
52 Haftanın En Düşük Seviyesi	AU$0.019
Beta	0.88
11 Aylık Değişim	60.00%
3 Aylık Değişim	33.33%
1 Yıllık Değişim	-55.56%
33 Yıllık Değişim	-66.67%
5 Yıllık Değişim	-74.19%
Halka arzdan bu yana değişim	-99.41%

Son Haberler & Güncellemeler

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Recent updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Hissedar Getirileri

	RNO	AU Pharmaceuticals	AU Pazar
7D	-7.0%	-2.3%	-1.1%
1Y	-55.6%	61.9%	16.1%

Getiri vs. Endüstri: RNO underperformed the Australian Pharmaceuticals industry which returned 61.8% over the past year.

Getiri vs Piyasa: RNO underperformed the Australian Market which returned 9.6% over the past year.

Fiyat Oynaklığı

Is RNO's price volatile compared to industry and market?
RNO volatility
RNO Average Weekly Movement	26.2%
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.6%

İstikrarlı Hisse Senedi Fiyatı: RNO's share price has been volatile over the past 3 months.

Zaman İçindeki Volatilite: RNO's weekly volatility has increased from 19% to 26% over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2004	n/a	Michael Johnson	www.rhinomed.global

Rhinomed Limited Temel Bilgiler Özeti

Rhinomed'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
RNO temel i̇stati̇sti̇kler
Piyasa değeri	AU$11.51m
Kazançlar(TTM)	-AU$10.91m
Gelir(TTM)	AU$8.05m

1.4x

P/S Oranı

-1.1x

F/K Oranı

RNO aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
RNO gelir tablosu (TTM)
Gelir	AU$8.05m
Gelir Maliyeti	AU$2.78m
Brüt Kâr	AU$5.28m
Diğer Giderler	AU$16.18m
Kazançlar	-AU$10.91m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.038
Brüt Marj	65.53%
Net Kâr Marjı	-135.49%
Borç/Özkaynak Oranı	-90.4%

RNO uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

RNO Stoklara Genel Bakış

Ödüller

Risk Analizi

Rhinomed Limited Rakipler

ASX:IVX

AU$13.5m

ASX:CAN

AU$20.2m

ASX:FRE

AU$12.0m

ASX:EMD

AU$13.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.02 loss in FY 2022)

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Market cap size

Insider recently bought AU$242k worth of stock

Insider recently bought AU$372k worth of stock

Is Rhinomed (ASX:RNO) Using Too Much Debt?

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Rhinomed Limited Temel Bilgiler Özeti

1.4x

-1.1x

Kazanç ve Gelir